Cenobamate for the treatment of focal epilepsies.

Adam StrzelczykCatrin MannLaurent Maximilian Willems Felix Rosenow Sebastian Bauer

Published in: Expert opinion on pharmacotherapy (2020)

Cenobamate has the potential to perform as an important ASD because trial data are indicative of remarkable responder and seizure freedom rates so far not seen with other ASDs. Cenobamate demonstrated significant efficacy at a dosage between 100 and 400 mg per day. The side-effect profile of this drug is comparable to other ASDs and is mainly CNS related; in particular, somnolence, dizziness, headache, diplopia, and nystagmus. However, slow titration is mandatory to decrease the risk of drug rash with eosinophilia and systemic symptoms (DRESS) that was observed in several patients with fast uptitration schemes.

Keyphrases

autism spectrum disorder
drug induced
study protocol
electronic health record
attention deficit hyperactivity disorder
blood brain barrier
adverse drug
big data
intellectual disability
sleep quality
depressive symptoms
combination therapy
climate change
data analysis
temporal lobe epilepsy